Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...
AbbVie
Allergan Aesthetics Partners with Sinopharm at CIIE for Aesthetic Medicine
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced a partnership with Sinopharm Group Co.,...
Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner...
Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite...
I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial
China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
I-Mab and AbbVie End CD47 Antibody Trial but Continue Collaboration
China-based biotech I-Mab (NASDAQ: IMAB) filed with the US Securities and Exchange Commission (SEC) that...
AbbVie’s Allergan Aesthetics CoolAdvantage Applicator Wins NMPA Approval
US-based AbbVie’s Allergan Aesthetics announced that it has received marketing approval from the National Medical...